Founded in 2018 and based on technology developed at the University of California San Francisco, Alessa Therapeutics is developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease. And have announced the enrollment of the first patient in the company’s Biolen-PC clinical study in Australia. Biolen-PC (NCT 04284761) is a first-in-man study evaluating the safety and patient tolerance of Biolen for the localized sustained delivery of bicalutamide into the prostate in patients scheduled for prostate surgery for treatment of non-metastatic prostate cancer. The Biolen-PC study will treat up to 20 patients in Australia and New Zealand.
